These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 27913941)

  • 1. The enigma of value: in search of affordable and accessible health care.
    Szucs TD; Weiss M; Klaus G
    Eur J Health Econ; 2017 Jul; 18(6):667-670. PubMed ID: 27913941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pill too hard to swallow: how the NHS is limiting access to high priced drugs.
    Gornall J; Hoey A; Ozieranski P
    BMJ; 2016 Jul; 354():i4117. PubMed ID: 27469086
    [No Abstract]   [Full Text] [Related]  

  • 4. The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare.
    Critchley GJ; Zaric GS
    Health Econ; 2019 Aug; 28(8):1035-1051. PubMed ID: 31310424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmaco-economics: a point of view of the mutualities].
    Legrand D; Simon I
    Rev Med Liege; 1998 May; 53(5):242-8. PubMed ID: 9689875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.
    Hu J; Mossialos E
    Health Policy; 2016 May; 120(5):519-34. PubMed ID: 27080345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Assessment of the pharmaceutical expenditure in Hungary].
    Inotai A; Merész G; Kaló Z
    Acta Pharm Hung; 2010; 80(4):162-72. PubMed ID: 21404477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern.
    Van Nuys K; Brookmeyer R; Chou JW; Dreyfus D; Dieterich D; Goldman DP
    Health Aff (Millwood); 2015 Oct; 34(10):1666-74. PubMed ID: 26438742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UK budgetary systems and new health-care technologies.
    McGuire A; Litt M
    Value Health; 2003; 6 Suppl 1():S64-73. PubMed ID: 12846927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When Opportunity Knocks, What Does It Say?
    Phelps CE
    Value Health; 2019 Aug; 22(8):851-853. PubMed ID: 31426924
    [No Abstract]   [Full Text] [Related]  

  • 13. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceuticals in U.S. health care: determinants of quantity and price.
    Berndt ER
    J Econ Perspect; 2002; 16(4):45-66. PubMed ID: 15179978
    [No Abstract]   [Full Text] [Related]  

  • 15. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.
    Gleeson D; Lopert R; Reid P
    Health Policy; 2013 Oct; 112(3):227-33. PubMed ID: 23992756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ISPOR's Initiative on US Value Assessment Frameworks: Seeking a Role for Health Economics.
    Sculpher M
    Value Health; 2018 Feb; 21(2):171-172. PubMed ID: 29477397
    [No Abstract]   [Full Text] [Related]  

  • 17. The management of the cost and utilisation of pharmaceuticals in the United Kingdom.
    Burstall ML
    Health Policy; 1997 Sep; 41 Suppl():S27-43. PubMed ID: 10174472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costly Cures.
    Booth M
    State Legis; 2017 Feb; 43(2):10-5. PubMed ID: 28157280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of the Price-Volume Approach in Cases of Innovative Drugs Where Value-Based Pricing is Inadequate: Description of Real Experiences in Italy.
    Messori A
    Clin Drug Investig; 2016 Aug; 36(8):599-603. PubMed ID: 27216427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High cost of new drugs.
    Mazzucato M
    BMJ; 2016 Jul; 354():i4136. PubMed ID: 27815284
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.